NDAORALFOR SOLUTIONPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
VIDEX (didanosine) by Bristol Myers Squibb is [ see clinical pharmacology () ]. Approved for hiv infection, aids. First approved in 1991.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIDEX (didanosine) is an oral nucleoside reverse transcriptase inhibitor (NRTI) approved in 1991 for treatment of HIV infection and AIDS. It works by inhibiting HIV reverse transcriptase, blocking viral replication in infected cells. This pioneering antiretroviral was among the first oral HIV therapies available.
LOE Approaching
Declining
Product approaching loss of exclusivity with minimal linked job opportunities; team likely in transition or consolidation mode.
Mechanism of Action
[ see Clinical Pharmacology () ].
Indications (2)
Clinical Trials (20)
A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals
15 enrolled
HIV Infections
Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children
198 enrolled
HIV Infections
Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults
200 enrolled
HIV Infections
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
256 enrolled
HIV Infections
A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine
24 enrolled
Cytomegalovirus InfectionsHIV Infections
Worked on VIDEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.